Cancer immunotherapies often rely on activating immune responses, yet many tumors remain resistant because their internal survival mechanisms are ...
Namodenoson (CF102), an investigational small-molecule A3 adenosine receptor (A3AR) agonist, has demonstrated favorable ...
Cancer immunotherapies often rely on activating immune responses, yet many tumors remain resistant because their internal survival mechanisms are poorly understood.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results